Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) presented positive results from the EVEREST Phase 4 trial in adults with severe chronic rhinosinusitis with nasal polyps and coexisting asthma. In the trial, Dupixent outperformed Xolair on all primary and secondary efficacy endpoints of CRSwNP, and in all asthma-related endpoints. The data are from the first-ever presented head-to-head respiratory trial with biologic medicines and were shared in a late-breaking oral presentation at the 2025 European Academy of Allergy and Clinical Immunology, EAACI, Annual Congress. Results reinforce the efficacy of Dupixent in treating both upper and lower respiratory diseases by targeting IL-4 and IL-13, two key drivers of type 2 inflammation
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on REGN:
- 23andMe confirms sale of business to TTAM Research Institute for $305M
- Regeneron: Attractive Valuation and Strong Growth Prospects Justify Buy Rating
- 27 states, DC, sue 23andMe over sale of DNA data, NY Times reports
- Regeneron Hold Rating: Eylea Developments and Future Pipeline Focus
- VOO ETF News, 6/9/2025
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue